SCHEMBL1663966

SCHEMBL1663966

Cc1cc(-n2c(C(C)C)nc3cc(O)ccc3c2=O)cnc1C#N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.67
ESR1 P03372 3/20 0.46
ESR2 Q92731 3/20 0.46
PIK3CD O00329 4/20 0.35
PIK3R1 P27986 3/20 0.35
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
HSD17B10 Q99714 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
AKR1B1 P15121 1/20 0.33
KCNJ1 P48048 2/20 0.33
TDP2 O95551 1/20 0.32
POLB P06746 1/20 0.32
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663868 0.87 TRPV1 (0.63) TRPV1ESR1ESR2PIK3CDPIK3R1
SCHEMBL1663887 0.84 TRPV1 (0.58) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL10446213 0.83 TRPV1 (0.72) TRPV1ESR1ESR2PIK3CDPIK3R1
SCHEMBL1663721 0.83 TRPV1 (0.72) TRPV1ESR1ESR2PIK3CDPIK3R1
SCHEMBL1663956 0.82 TRPV1 (0.56) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1663738 0.80 TRPV1 (0.65) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL29383546 0.80 TRPV1 (1.00) TRPV1ESR1ESR2PIK3CDPIK3R1
SCHEMBL1066896 0.80 TRPV1 (1.00) TRPV1ESR1ESR2PIK3CDPIK3R1
SCHEMBL10446410 0.80 TRPV1 (0.67) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1666196 0.79 TRPV1 (0.63) TRPV1ESR1ESR2PIK3CDPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.